Ingmar Gorman

Dr. Ingmar Gorman is a psychologist who specializes in assisting populations who have had experiences with psychedelics. He is the co-founder of Fluence, which trains mental health providers in psychedelic integration and therapy.

CV

He is the site co-principal investigator and therapist on a MAPS Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. He also co-founded the Psychedelic Education and Continuing Care Program in 2015 and directed the program until 2019. Dr. Gorman is a board member of Horizons Media, Inc., a not-for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics. He completed his NIH funded postdoctoral fellowship at New York University in 2019.

Notable Research Papers

• Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder (Gorman et al., 2020)
• Use of LSD by Mental Health Professionals (Winkler et al., 2016)
• Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics (Páleníček et al., 2011)

Find more on Google Scholar or PubMed

In our database you will also find him as an author on many more papers.

Media

He has given public talks:

• THE PERFECT PSYCHEDELIC EXPERIENCE – Dr. Ingmar Gorman & Dr. Elizabeth Nielson (Third Wave, January 2019)
• Horizons 2018: INGMAR GORMAN, PH.D. & WILLA HALL, PH.D. “MDMA-Assisted Clinical Study of PTSD” (Horizons, 2018)
• MICRODOSING with Caution – Ingmar Gorman, PhD (Third Wave, April 2018)
• Horizons 2016: KATHERINE MACLEAN, Ph.D. & INGMAR GORMAN, M.A. “Psychedelic Integration” (Horizons, 2016)

More media:

• Psychedelic Therapy Schools Are Popping Up Like Mushrooms (Bloomberg, January 2021)
• Therapists Are Unprepared to Talk to People About Taking Psychedelics (Vice, March 2020)